New study tests if adding a biologic drug helps kids with arthritis

NCT ID NCT07386587

ENROLLING_BY_INVITATION Disease control Sponsor: University of Child Health Sciences and Children's Hospital, Lahore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial in Lahore, Pakistan, will enroll 60 children aged 2–16 with newly diagnosed polyarticular juvenile idiopathic arthritis. Half will receive methotrexate alone, and half will receive methotrexate plus etanercept, a biologic drug. Researchers will measure how many children achieve low disease activity over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methotrexate and etanercept
What this could lead to: If successful, this could show that adding etanercept to methotrexate helps more children with juvenile idiopathic arthritis reach low disease activity.
What could go wrong: This is a small, single-center trial with only 60 participants, so results may not apply broadly. Etanercept can increase infection risk and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE IDIOPATHIC ARTHRITIS

Contacts and locations

Show contact details

Locations

University of Child Health Sciences Lahore, The Children's hospital Lahore

Lahore, Punjab Province, 54600, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.